✦ LIBER ✦

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma

✍ Scribed by Andrea L. Harzstark; Eric J. Small; Vivian K. Weinberg; Janine Sun; Charles J. Ryan; Amy M. Lin; Lawrence Fong; Dion R. Brocks; Jonathan E. Rosenberg

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 131 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25931

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 3 trial of everolimus for metastat

Phase 3 trial of everolimus for metastatic renal cell carcinoma : Final results and analysis of prognostic factors

✍ Robert J. Motzer; Bernard Escudier; Stephane Oudard; Thomas E. Hutson; Camillo P 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 426 KB 👁 2 views

A phase 2 study with a daily regimen of

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

✍ Robert J. Amato; Jaroslaw Jac; Sarah Giessinger; Somyata Saxena; James P. Willis 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

Phase II study of lenalidomide in patien

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma

✍ Toni K. Choueiri; Robert Dreicer; Brian I. Rini; Paul Elson; Jorge A. Garcia; Sn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB 👁 1 views

A phase II trial of palliative radiother

A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma

✍ Justin Lee; David Hodgson; Edward Chow; Andrea Bezjak; Pamela Catton; Debbie Tsu 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 2 views

A Phase II trial of bryostatin-1 for pat

A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma

✍ Lance Pagliaro; Danai Daliani; Robert Amato; Shi-Ming Tu; Donnah Jones; Terry Sm 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 2 views

A phase II study of constant-infusion fl

A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma

✍ Mary J. Wilkinson; John W. Frye; Eric J. Small; Alan P. Venook; Peter R. Carroll 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 2 views

Background. Twenty-nine patients with metastatic renal cell carcinoma (RCC) were treated with constantinfusion floxuridine (FUdR, Roche Laboratories, Nut-Methods. The initial dosage was 0.075 mg/kg/day for 14 days every 28 days and was increased or decreased by 0.025-mg/kg/day increments at each sub